CrystalsFirst GmbH
Our mission is to provide the world‘s most advanced service platform to unlock chemical matter and help to bring the most innovative medicines to patients. Since the inception of the company, we have successfully pioneered our “structural data first” approach to unlock untapped potential of difficult targets. CrystalsFirst provides cutting-edge solutions to unlock chemical matter for protein targets. Our discovery platform and flexible business model have a proven track record of successful campaign with global pharma and biotech companies.
Company details
Find locations served, office locations
- Business Type:
- Technology
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Internationally (various countries)
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
Our Story
What started with a crazy idea from an observation in the lab of Prof. Gerhard Klebe, has become a recognized service provider in biotech and pharma.
We offer top-notch drug discovery and high-performance structural biology services. We offer cutting-edge technology and experience to support with drug discovery projects across protein families and modalities. We provide a variety of stand-alone packages for crystallographic fragment screening and co-structure determination addressing non-covalent, and covalent modalities as well as cryptic sites. We also offer integrated drug research, from early drug discovery to preclinical development.
Since its inceptions in Marburg, we have expanded in 2022 to Hamburg. We have labs and offices at the Germany’s largest synchrotron facility DESY.
What Partners Say About Us
CrystalsFirst's platform significantly improved the crystallographic quality and unlocked the potential for a novel inhibition mechanism of our target of interest. Their team is distinguished by flexible problem skills and pro-active communication. We absolutely recommend CrystalsFirst's expertise and services to other companies!